TGF-β Inhibitors in Metastatic Pancreatic Ductal Adenocarcinoma
2019
Background
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancerrelated mortality in the USA, and the overall incidence of the disease is increasing such that it is expected to be the third leading cause of cancer-related deaths in the next decade. Minimal improvements in therapy have not changed the overall mortality rate over the past decade for patients with PDAC. The purpose of this review is to identify new data regardign the role of Transforming growth factor beta (TGF-β) based therapeuics in patients with PDAC.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
60
References
19
Citations
NaN
KQI